Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05623956 | Proteomics in Small Cell Lung Cancer(SCLC-OMICS) | unknown | — | 50 | Aalborg University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06586697 | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06558903 | Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)(HYPE) | unknown | — | 20 | University Hospital, BrestOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06530797 | A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer | unknown | — | 2,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04562337 | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC | unknown | Phase 2 | 67 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483919 | The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer | unknown | — | 228 | Jinming YuOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06406660 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT05443646 | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06402695 | Observational Study on GEP-and Pulm-NET Treated at FPG(ETNA-FPG) | unknown | — | 650 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06364046 | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | unknown | N/A | 56 | The Central Hospital of Lishui CityOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05254119 | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS(REGISTURK-LUNG) | unknown | — | 6,000 | Mahmut GumusNETWORK | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06323265 | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | unknown | — | 50 | Hebei Medical University Fourth HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06293833 | Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan(ZORALCS) | unknown | N/A | 700 | University Hospital, AntwerpOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06267170 | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer(SCLC) | unknown | — | 288 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 20, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05296603 | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 83 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05991180 | Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | — | 160 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04985851 | To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | unknown | N/A | 90 | Shanghai Chest HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05228496 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05896059 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05769504 | Examining Clinical Trial Participation for Small Cell Lung Cancer Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05668767 | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | unknown | Phase 2 | 20 | Beijing Chest HospitalOTHER | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | unknown | N/A | 33 | Haibo ZhangOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 31, 2025source: clinicaltrials